Moleculin Biotech (NASDAQ:MBRX) Trading Down 3.5% – What’s Next?

Moleculin Biotech, Inc. (NASDAQ:MBRX) was down 3.5% during trading on Wednesday . The stock traded as low as $4.06 and last traded at $4.14. Approximately 104,290 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 447,868 shares. The stock had previously closed at $4.29.

Analyst Upgrades and Downgrades

MBRX has been the topic of several research reports. Roth Capital reiterated a “buy” rating on shares of Moleculin Biotech in a research note on Monday, December 15th. Wall Street Zen lowered Moleculin Biotech to a “strong sell” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price objective (up previously from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Moleculin Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $61.00.

Moleculin Biotech Stock Down 3.5%

The firm’s 50 day simple moving average is $6.58 and its 200 day simple moving average is $10.75. The company has a market cap of $8.43 million, a price-to-earnings ratio of -0.13 and a beta of 1.62.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. Analysts anticipate that Moleculin Biotech, Inc. will post -7.98 EPS for the current fiscal year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.